<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393457</url>
  </required_header>
  <id_info>
    <org_study_id>DA030787</org_study_id>
    <nct_id>NCT01393457</nct_id>
  </id_info>
  <brief_title>Cognitive Remediation for Cocaine Dependence</brief_title>
  <official_title>Cognitive-enhancing DA Medications for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate treatments designed to improve cocaine treatment
      success by combining medications that target cocaine-related cognitive impairments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use Based on Urine Drug Screening</measure>
    <time_frame>10 weeks</time_frame>
    <description>The mean of the predicted probabilities (derived from generalized linear mixed models) of negative drug screens over all 10 weeks is reported, as per the analysis proposed in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Completed the 10 Week Trial</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>ldopa + ropinirole low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ldopa + ropinirole high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ldopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levodopa/carbidopa 800/200 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa/carbidopa</intervention_name>
    <description>800/200 mg/d</description>
    <arm_group_label>ldopa + ropinirole low dose</arm_group_label>
    <arm_group_label>ldopa + ropinirole high dose</arm_group_label>
    <arm_group_label>ldopa</arm_group_label>
    <other_name>ldopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole 2 mg/d</intervention_name>
    <description>2 mg/d</description>
    <arm_group_label>ldopa + ropinirole low dose</arm_group_label>
    <other_name>Requip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sugar pill</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole 4 mg/d</intervention_name>
    <description>4 mg/d</description>
    <arm_group_label>ldopa + ropinirole high dose</arm_group_label>
    <other_name>Requip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  meet criteria for cocaine dependence

          -  seeking treatment for cocaine dependence

          -  be in acceptable health based on medical history and physical exam

        Exclusion Criteria:

          -  dependent on drugs other than cocaine, nicotine, marijuana

          -  have a medical condition contraindicating treatment with study medications

          -  having conditions of probation or parole requiring reports of drug use to officers of
             the court
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Behavioral and Biomedical Sciences Building</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <results_first_submitted>February 23, 2018</results_first_submitted>
  <results_first_submitted_qc>March 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2018</results_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Joy Schmitz</investigator_full_name>
    <investigator_title>Professor - Psychiatry</investigator_title>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>cognition</keyword>
  <keyword>medication</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>119 were enrolled (that is, signed the consent); however, only 110 were randomized. Of the 9 that were not enrolled but not randomized, 1 was no longer interested after signing the consent, and 8 were lost to follow up.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ldopa + Ropinirole Low Dose</title>
          <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 2 mg/d: 2 mg/d</description>
        </group>
        <group group_id="P2">
          <title>Ldopa + Ropinirole High Dose</title>
          <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 4 mg/d: 4 mg/d</description>
        </group>
        <group group_id="P3">
          <title>Ldopa</title>
          <description>levodopa/carbidopa 800/200 mg/d</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ldopa + Ropinirole Low Dose</title>
          <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 2 mg/d: 2 mg/d</description>
        </group>
        <group group_id="B2">
          <title>Ldopa + Ropinirole High Dose</title>
          <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 4 mg/d: 4 mg/d</description>
        </group>
        <group group_id="B3">
          <title>Ldopa</title>
          <description>levodopa/carbidopa 800/200 mg/d</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.96" spread="6.50"/>
                    <measurement group_id="B2" value="46.04" spread="8.70"/>
                    <measurement group_id="B3" value="48" spread="7.87"/>
                    <measurement group_id="B4" value="47.11" spread="8.56"/>
                    <measurement group_id="B5" value="46.6" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of days of cocaine use over the last 30 days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.12" spread="8.08"/>
                    <measurement group_id="B2" value="16.31" spread="9.64"/>
                    <measurement group_id="B3" value="17.19" spread="8.46"/>
                    <measurement group_id="B4" value="14.74" spread="8.69"/>
                    <measurement group_id="B5" value="16.13" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use Based on Urine Drug Screening</title>
        <description>The mean of the predicted probabilities (derived from generalized linear mixed models) of negative drug screens over all 10 weeks is reported, as per the analysis proposed in the protocol.</description>
        <time_frame>10 weeks</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Ldopa + Ropinirole Low Dose</title>
            <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 2 mg/d: 2 mg/d</description>
          </group>
          <group group_id="O2">
            <title>Ldopa + Ropinirole High Dose</title>
            <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 4 mg/d: 4 mg/d</description>
          </group>
          <group group_id="O3">
            <title>Ldopa</title>
            <description>levodopa/carbidopa 800/200 mg/d</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use Based on Urine Drug Screening</title>
          <description>The mean of the predicted probabilities (derived from generalized linear mixed models) of negative drug screens over all 10 weeks is reported, as per the analysis proposed in the protocol.</description>
          <population>intention to treat</population>
          <units>number of negative drug screens</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.36" spread="29.51"/>
                    <measurement group_id="O2" value="15.57" spread="21.96"/>
                    <measurement group_id="O3" value="22.3" spread="28"/>
                    <measurement group_id="O4" value="27.8" spread="30.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Completed the 10 Week Trial</title>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ldopa + Ropinirole Low Dose</title>
            <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 2 mg/d: 2 mg/d</description>
          </group>
          <group group_id="O2">
            <title>Ldopa + Ropinirole High Dose</title>
            <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 4 mg/d: 4 mg/d</description>
          </group>
          <group group_id="O3">
            <title>Ldopa</title>
            <description>levodopa/carbidopa 800/200 mg/d</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Completed the 10 Week Trial</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>weekly for 10 weeks</time_frame>
      <desc>Side effects were not considered to be adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ldopa + Ropinirole Low Dose</title>
          <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 2 mg/d: 2 mg/d</description>
        </group>
        <group group_id="E2">
          <title>Ldopa + Ropinirole High Dose</title>
          <description>levodopa/carbidopa: 800/200 mg/d
Ropinirole 4 mg/d: 4 mg/d</description>
        </group>
        <group group_id="E3">
          <title>Ldopa</title>
          <description>levodopa/carbidopa 800/200 mg/d</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Gout flare up</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide ideation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Green, PhD</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-500-6402</phone>
      <email>charles.green@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

